The value of F-18-fluorodeoxyglucose Positron Emission Tomography for detection of Metastatic Infectious foci complicating gram-positive bacteraemia
- Conditions
- Infections and InfestationsMetastatic infection/ gram-positive bacteraemia
- Registration Number
- ISRCTN76425553
- Lead Sponsor
- niversity Medical Centre St. Radboud (The Netherlands)
- Brief Summary
2005 Other publications in https://pubmed.ncbi.nlm.nih.gov/16330565 2007 Other publications in https://pubmed.ncbi.nlm.nih.gov/17211607 2012 Results article in https://pubmed.ncbi.nlm.nih.gov/22391470/ (added 25/10/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 115
1. All patients with blood cultures containing one of the following micro-organisms:
a. Streptococcus aureus
b. Streptococcus species (excluding S. pneumoniae)
c. Enterococcus species
2. AND at least one of the following risk factors for metastatic infection:
a. Community acquired infection
b. Signs of infection for more than 48 hours before initiation of appropriate treatment
c. Skin lesions or other symptoms or signs pointing to possible metastatic infection
d. Fever lasting for more than 72 hours after initiation of appropriate treatment
e. Positive blood cultures for more than 48 hours after initiation of appropriate treatment
3. Informed consent
1. Age less than 18 years
2. Polymicrobial infection
3. Pregnancy
4. Critically ill patients initially admitted to the Intensive Care Unit (ICU) department for more than 14 days
5. Chemotherapeutically induced neutropenia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relapse rate of infection
- Secondary Outcome Measures
Name Time Method <br> 1. Attributable mortality<br> 2. Mortality after relapse<br> 3. Duration of first admission<br> 4. Duration of antibiotic treatment<br> 5. Number of diagnostic procedures performed to confirm metastatic foci, duration of admission due to relapse<br> 6. Associated costs<br>